SEC Form 4 · accession 0000886163-19-000005

LIGAND PHARMACEUTICALS INC · LGND

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Gen. Counsel & Secretary

Period of report

Jan 10, 2019

Accepted (ET)

Jan 14, 2019 · 9:17 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000886163

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jan 10, 2019	M	244	$21.92	A	37,307	D
Common Stock	Jan 10, 2019	M	1,931	$74.42	A	39,238	D
Common Stock	Jan 10, 2019	M	675	$56.26	A	39,913	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1	$21.92	Jan 10, 2019	M	244	D	—	Feb 15, 2023	Common Stock	244	0	D
Employee Stock Option (right to buy)^F2	$56.26	Jan 10, 2019	M	675	D	—	Feb 10, 2025	Common Stock	675	2,617	D
Employee Stock Option (right to buy)^F3	$74.42	Jan 10, 2019	M	1,931	D	—	Feb 12, 2024	Common Stock	1,931	0	D

F1Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
F2Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/10/15.
F3Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14.